IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Helene AUDRAIN et al.

Serial No.: To be assigned

Art Unit: To be assigned

Filing Date: Concurrently herewith

Examiner: To be assigned

For: Process

· 🔭 - 😭

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[] Co [X] A	pies of the references are enclosed pies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) copy of the International Search Report which issued on International Application No PCT/EP2004/008830 is submitted herewith. All of the publications cited in the remational Search Report are listed on the attached form PTO-1449 and Applicants understand that pies have been supplied to the U.S. Patent Office by the International Bureau.					
Α.	[X] The Information Disclosure Statement submitted herewith is being filed within three months filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).						
	OR						
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).					
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.					
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.					
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00)					

APZOROVALIZATO 07 FEB 2006

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under
		1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the
		issue fee. Also enclosed is a copy of the International Search Report which Issued on International
		Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

James P. Riek Attorney of Record

Registration No. 39,009

Date: Fel 7 2006

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8022 Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO. PB60434USw APPLICANT		serial no 67524			
					Helene AUDRAIN et al.					
					FILING DATE GROUP					
					Concurrently herewith		To be assigned			
			U.S. I	PATENT D	OCUMENTS	<u> </u>	•			
Examiner	Patent		Issue Date	Name	Class	Subclass	Filing Date If Appropriate			
Initials		Number								
							-			
						_				
						<u> </u>				
				ontinue on p						
			FOREIG	N PATENT	T DOCUMENTS					
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No		
					•					
			,							
			ļ	ļ						
		<u> </u>	<u> </u>	ļ						
		<u> </u>			<u>-</u>			<u> </u>		
								<u> </u>		
				<u> </u>				<u> </u>		
				ontinue on p						
		OTHER DOCUM	MENTS (Includi	ng Author,	Title, Journal-D	ate, Page Num	ber, Etc.)			
`	1.	Alberto et al., "Synthesis and properties of boranocarbonate: a convenient in situ co source for the aqueous preparation of [99MTc(OH ₂) ₃ (CO) ₃] +," <i>Journal of the American Chemical Society</i> 123:3135-3136 (Mar. 2001)								
	2.	Jones et al., "Potential constants of borane carbonyl ^a ," Journal of Chemical Physics 70(2) :749-757 (Jan. 1979)								
	3.	Venkatachar et al., "Microwave spectrum, structure, quadrupole coupling constants and dipole moment of carbon monoxide-borane," <i>Journal of Molecular Structure</i> 38:17-23 (1977).								
		Carbon monoxide	-oorane, Journa	и ој могеси	iar structure 36:1	1-23 (1911).		-		
		 	· · · · · · · · · · · · · · · · · · ·							
		 								
										
	-	+		·						
		٠.		Continue on	nage					
EXAMINER				Zantinue on	puge	DATE	CONSIDERE	D		
	•						_ JJ. DDIAL	_		
EXAMINER	: Initi	ial if citation consid	ered, whether or	not citation	is in conformance	with MPEP & 6	609; Draw line	e through		
		nformance and not								